治疗药物性精神病

IF 3.7 4区 医学 Q1 PSYCHIATRY International Review of Psychiatry Pub Date : 2023-09-24 DOI:10.1080/09540261.2023.2261544
Leonardo Baldaçara, Artur Ramos, João Maurício Castaldelli-Maia
{"title":"治疗药物性精神病","authors":"Leonardo Baldaçara, Artur Ramos, João Maurício Castaldelli-Maia","doi":"10.1080/09540261.2023.2261544","DOIUrl":null,"url":null,"abstract":"AbstractSubstance-induced psychosis is a secondary psychotic disorder resulting from drug abuse, characterized by one or more psychotic episodes. Drug-induced psychosis is expected to resolve after a 30-day period of sobriety, however, individuals with this condition are more likely to develop severe drug addiction. Compared to primary psychosis, participants with drug-induced psychosis exhibit poorer family history of psychotic diseases, higher insight, fewer positive and negative symptoms, more depressive symptoms, and greater anxiety. Substance-induced psychosis is strongly associated with the emergence of bipolar illness or schizophrenia spectrum disorder, with an increased chance of developing schizophrenia at a younger age. Episodes of self-harm after substance-induced psychosis are strongly linked to an elevated likelihood of developing schizophrenia or bipolar disorder. Effective treatment involves ruling out emergencies, investigating underlying causes, and addressing acute intoxication and withdrawal. Management includes dynamic assessment, intervention, and vigilant monitoring in cases of suicidal behaviour. Antipsychotics may be used for short term, with gradual discontinuation when a person is in a stable condition. Relapse prevention strategies, both medication and non-medication-based, are crucial in long-term management. Conversion rates to schizophrenia or bipolar disorder can be as high as one in three individuals, with cannabis users and those with early-onset substance abuse at the highest risk.Keywords: Drug-induced psychosispsychotic disordersbipolar disorderschizophreniarisk Authors’ contributionAll authors participated in all stages of the review.Disclosure statementLB worked as a scientific consultant for Libbs and Jansen. The other authors have no conflicts of interest to declare.","PeriodicalId":51391,"journal":{"name":"International Review of Psychiatry","volume":"7 1","pages":"0"},"PeriodicalIF":3.7000,"publicationDate":"2023-09-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Managing drug-induced psychosis\",\"authors\":\"Leonardo Baldaçara, Artur Ramos, João Maurício Castaldelli-Maia\",\"doi\":\"10.1080/09540261.2023.2261544\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"AbstractSubstance-induced psychosis is a secondary psychotic disorder resulting from drug abuse, characterized by one or more psychotic episodes. Drug-induced psychosis is expected to resolve after a 30-day period of sobriety, however, individuals with this condition are more likely to develop severe drug addiction. Compared to primary psychosis, participants with drug-induced psychosis exhibit poorer family history of psychotic diseases, higher insight, fewer positive and negative symptoms, more depressive symptoms, and greater anxiety. Substance-induced psychosis is strongly associated with the emergence of bipolar illness or schizophrenia spectrum disorder, with an increased chance of developing schizophrenia at a younger age. Episodes of self-harm after substance-induced psychosis are strongly linked to an elevated likelihood of developing schizophrenia or bipolar disorder. Effective treatment involves ruling out emergencies, investigating underlying causes, and addressing acute intoxication and withdrawal. Management includes dynamic assessment, intervention, and vigilant monitoring in cases of suicidal behaviour. Antipsychotics may be used for short term, with gradual discontinuation when a person is in a stable condition. Relapse prevention strategies, both medication and non-medication-based, are crucial in long-term management. Conversion rates to schizophrenia or bipolar disorder can be as high as one in three individuals, with cannabis users and those with early-onset substance abuse at the highest risk.Keywords: Drug-induced psychosispsychotic disordersbipolar disorderschizophreniarisk Authors’ contributionAll authors participated in all stages of the review.Disclosure statementLB worked as a scientific consultant for Libbs and Jansen. The other authors have no conflicts of interest to declare.\",\"PeriodicalId\":51391,\"journal\":{\"name\":\"International Review of Psychiatry\",\"volume\":\"7 1\",\"pages\":\"0\"},\"PeriodicalIF\":3.7000,\"publicationDate\":\"2023-09-24\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"International Review of Psychiatry\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1080/09540261.2023.2261544\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"PSYCHIATRY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Review of Psychiatry","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/09540261.2023.2261544","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PSYCHIATRY","Score":null,"Total":0}
引用次数: 0

摘要

摘要物质诱发性精神病是一种由药物滥用引起的继发性精神障碍,以一次或多次精神病发作为特征。药物引起的精神病预计在30天的清醒期后会消退,然而,有这种情况的人更有可能发展成严重的药物成瘾。与原发精神病患者相比,药物性精神病患者表现出较差的精神病家族史,更高的洞察力,较少的阳性和阴性症状,更多的抑郁症状和更大的焦虑。物质诱发的精神病与双相情感障碍或精神分裂症谱系障碍的出现密切相关,在年轻时发展为精神分裂症的机会增加。药物诱发精神病后的自残发作与发展为精神分裂症或双相情感障碍的可能性增加密切相关。有效的治疗包括排除紧急情况,调查潜在原因,处理急性中毒和戒断。管理包括对自杀行为的动态评估、干预和警惕监测。抗精神病药物可短期使用,当患者病情稳定时可逐渐停药。预防复发策略,无论是药物治疗还是非药物治疗,都是长期治疗的关键。转化为精神分裂症或双相情感障碍的比率可高达三分之一,大麻使用者和早发性药物滥用者的风险最高。关键词:药物性精神、精神障碍、双相情感障碍、精神分裂症风险所有作者均参与了本综述的所有阶段。披露声明lb曾担任Libbs和Jansen的科学顾问。其他作者没有利益冲突需要申报。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Managing drug-induced psychosis
AbstractSubstance-induced psychosis is a secondary psychotic disorder resulting from drug abuse, characterized by one or more psychotic episodes. Drug-induced psychosis is expected to resolve after a 30-day period of sobriety, however, individuals with this condition are more likely to develop severe drug addiction. Compared to primary psychosis, participants with drug-induced psychosis exhibit poorer family history of psychotic diseases, higher insight, fewer positive and negative symptoms, more depressive symptoms, and greater anxiety. Substance-induced psychosis is strongly associated with the emergence of bipolar illness or schizophrenia spectrum disorder, with an increased chance of developing schizophrenia at a younger age. Episodes of self-harm after substance-induced psychosis are strongly linked to an elevated likelihood of developing schizophrenia or bipolar disorder. Effective treatment involves ruling out emergencies, investigating underlying causes, and addressing acute intoxication and withdrawal. Management includes dynamic assessment, intervention, and vigilant monitoring in cases of suicidal behaviour. Antipsychotics may be used for short term, with gradual discontinuation when a person is in a stable condition. Relapse prevention strategies, both medication and non-medication-based, are crucial in long-term management. Conversion rates to schizophrenia or bipolar disorder can be as high as one in three individuals, with cannabis users and those with early-onset substance abuse at the highest risk.Keywords: Drug-induced psychosispsychotic disordersbipolar disorderschizophreniarisk Authors’ contributionAll authors participated in all stages of the review.Disclosure statementLB worked as a scientific consultant for Libbs and Jansen. The other authors have no conflicts of interest to declare.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
5.10
自引率
0.00%
发文量
85
期刊介绍: The International Review of Psychiatry is the premier review journal in the field with a truly international authorship and readership. Each bimonthly issue is dedicated to a specific theme relevant to psychiatry, edited by recognized experts on the topic, who are selected by the Editors and the Editorial Board. Each issue provides in-depth, scholarly reviews of the topic in focus. The Journal reaches a broad international readership including clinicians, academics, educators, and researchers who wish to remain up-to-date with recent and rapid developments in various fields of psychiatry. It aims to be of value to trainees by choosing topics of relevance to career development, which are also suitable for clinicians for continuing professional development.
期刊最新文献
The splendors and miseries of narrativity the virtue of the fragment and the formation of clinicians in XXI century Psychedelic medicine in psychiatry residency training: a survey of psychiatric residency program directors Clinicians’ perspectives on strategies for suicide prevention in Pakistan: a qualitative inquiry Considering distinct positive emotions in psychedelic science The many facets of physical activity, sports, and mental health
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1